Telehealth Prescribing

Telehealth prescribing is the issuing of a prescription following a remote encounter rather than an in-person examination. At one end sits synchronous video consultation with a clinician who holds the patient's records and arranges follow-up laboratory work; at the other sits asynchronous prescribing, where a patient completes a structured questionnaire, a clinician licensed in the patient's jurisdiction reviews it without speaking to them, and an order goes to a dispensing pharmacy. Both are lawful in many places, and they are not remotely equivalent clinically.

The regulatory scaffolding is jurisdictional and uneven. Prescribers must generally be licensed where the patient is located rather than where the platform is based. Controlled substances carry an additional layer in the United States under the Ryan Haight Act, whose in-person evaluation requirement was suspended by flexibilities beginning in 2020 and repeatedly extended; most therapeutic peptides are not controlled substances, so that debate largely bypasses them.

What changes the analysis is the platform's business model. Where the same company owns the questionnaire, employs or contracts the prescriber, and dispenses the product, the clinical decision and the sale are made by one commercial entity. That is a structural conflict of interest independent of any clinician's integrity, and it shows up as high approval rates and a narrow formulary.

The error is inferring that a prescription implies individualised assessment. A prescription evidences that a licensed person accepted responsibility for the order, nothing more. When the platform also sells a compounded preparation, the prescription is additionally the legal basis for compounding, a regulatory requirement rather than a clinical endorsement.